Introduction
Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are characterized by a series of cytogenetic aberrations and mutations genes tightly connected with the leukemogenic process [1] . A prominent characteristic of MDS is its genetic instability, and nearly 30% of MDS cases will develop into AML [2] [3] [4] . In addition, AML and MDS that occur commonly in older patients, and the diagnostic median age is 67 years (54% diagnosed age at 65 years or older) [5] . Although some treatments had improved the quality life of patients, the prognosis value was still very poor. According to Surveillance, Epidemiology and End Results data, the five-year survival rates from 2007 to 2012 was 26% for AML patients [6] . Therefore, to find the prognosis factors seem to be much important for the patients with AML and MDS.
Ras oncogenes encode a family of membrane-associated proteins that regulate signal transduction on binding to a variety of membrane receptors. There are 3 functional ras genes-Nras, Kras, and Hras-and all homologs carry mutations nearly exclusively in codons 12, 13, and 61, conferring constitutive activation of the RAS protein, which subsequently is held in GTP-bound status [7] . Ras mutations have been described in various solid tumors and in hematologic 5th International Conference on Advanced Materials and Computer Science (ICAMCS 2016) malignancies [7] . Nras mutations seem to be the most prominent ras mutations in patients with AML and MDS [8] . Reuter et al found that transforming noncanonical Nras mutations at codon 60 and Kras mutations at codons 14, 74, and 146 were detected in primary leukemia samples, indicating that the prevalence of activating ras mutations may be underestimated in leukemia [9] .
Although the high frequency of ras mutations was detected in patients with AML and MDS, the overall prognostic impact of mutations in patients with AML and MDS is controversial. Some investigators reported that ras mutations were associated with an adverse outcom [10] , others have noted no significant prognostic impact [10] . Most previous studies didn't consider the subtype of ras, such as Nras, Kras or Hras and we suppose that this may be one reason that results in controversial. To demonstrate our supposition and clarify the relationship between ras gene mutations and the prognosis for patients with AML and MDS, it is necessary to perform a systematic review and meta-analysis of the published studies to derive a more precise estimation.
Methods
The results of a study were considered significant if the p-value for the statistical test comparing the survival distribution between the groups with and without abnormalities in the status of ras was < 0.05. The study was then called "positive" (which meant that alteration was a poor prognosis for survival). If authors reported a significant result in a subgroup analysis only, the study was also considered to be positive. In addition, a study was called "negative" which reporting non-significant results or identifying ras gene mutations as associated with better survival. With regard to the quality scores, the scores of the studies were measured by the mean, standard deviation and range. Nonparametric tests were used to compare the distribution of the quality scores according the Mann-Whitney U test.
The effect of ras gene mutations on OS was measured by the pooled HR and 95% CI. For each trial, this HR was estimated by a method depending on the results provided in a previous publication [11] . If articles did not provide the HR, the numbers of patients at risk in each group, and the logrank statistic or its p-value were used to allow for an approximate calculation of the HR. If the only exploitable data were in form of graphical representations of the survival distributions, the data from Kaplan-Meier survival curves was read by Engauge Digitizer version 2.11, and the minimum and maximum follow-up periods were obtained from the articles [12] . The statistical heterogeneity within studies was evaluated using a χ2-based Cochran's Q statistic [13] and was further quantified using I2 statistics (I2 = 0-25%, no heterogeneity; I2 = 25-50%, moderate heterogeneity; I2 = 50-75%, large heterogeneity; and I2 =75-100%, extreme heterogeneity. For values of I2 ≤ 50%, the fixed-effects model was used; I2 ≥ 50%, the random-effects model was used) [13] . AML group. 18 studies (75%) independently researched the relationship between ras mutation and the prognosis with AML patients. The pooled HR for the association between ras gene mutations and the OS in patients with AML was 1.10 (95% CI, 0.97-1.26, p= 0.15), with moderate heterogeneity between studies (I2= 33.87, p= 0.07). It was determined that ras gene mutations seem not to correlate with the prognosis of patients with AML (Fig.1A) . A funnel plot identified the presence of publication bias, and Duval and Tweedie's trim-and-fill analysis was used to adjust the HR (Fig.1B) , with p= 0.15 in the Begg rank correction test and p= 0.11 in Egger's linear regression test.
Results

Meta-analysis
MDS group. 6 studies (25%) independently researched the relationship between ras mutation and the prognosis with MDS patients. The pooled HR for the association between ras gene mutations and the OS in patients with MDS was 1.89 (95% CI, 1.56-2.30, p<0.001), without heterogeneity between studies (I2=0, p=0.47). It was determined that ras gene mutation correlate with the poor prognosis of patients with MDS (Fig.1C) . A funnel plot identified the presence of publication bias, and Duval and Tweedie's trim-and-fill analysis was used to adjust the HR (Fig.1D) , with p=0.57 in the Begg rank correction test and p=0.88 in Egger's linear regression test.
Discussion
Clinical heterogeneity is reflected by genetic findings with trisomy 8 and 22, KIT, and FLT3 mutations representing prognostic markers [14] . However, ras gene mutations as a prognostic factor for AML and MDS remain inconclusive. To our knowledge, this study is the first meta-analysis that explored the independent prognosis between ras gene mutations and patients of AML and MDS. Identification of independent prognostic factors allowed for the definition of high-risk groups of patients for whom specific therapy could be designed or a stratification in randomized trials performed. So far, for AML and MDS, useful prognostic factors are specific cytogenetic abnormalities, specific molecular markers, and percentage of marrow blasts and severity of cytopaenias [3] [15] .
We extracted twenty-four studies that included 717 mutation cases among 5,704 patients. Nine sets of data indicated that ras gene mutations were associated with poor prognosis for patients with AML or MDS. Fifteen sets of data indicated that not any statistically significant association between ras gene mutations and OS. Based on our systematic review of literature with meta-analysis shows that ras gene mutations seem not to correlate with the prognosis of patients with AML, but exists a poor prognosis of patients with MDS if take no account of the type of ras mutations. In subgroup analysis, the poor prognostic value of AML is observed in Asia region, ONH method and publication year before 2000. In addition, all prognostic value of MDS is poor. Summarily, based on our subgroup analysis, the pooled HR may be affected by study regions, detection methods and year of publication. However, the relatively small sample size may not have enough statistical power to detect the association between ras gene mutations and survival and the results still need to be confirmed by an adequately designed prospective study and the exact value of an ras alteration needs to be determined by an appropriate multivariate analysis, taking into account the classical well-defined prognostic factors for AML and MDS.
Summary
To conclude, we demonstrated that our previous supposition that take no account of the type of ras may be one reason that results in controversial. Take no account of the type of ras, in the present systematic review with meta-analysis, ras mutations seem not to correlate with the prognosis of patients with AML but a poor prognostic value for survival in patients with MDS, however, further research subtype of ras, we confirmed that there was a poor prognosis in AML patients with Nras and Kras and an unfavorable impact on survival in MDS patients with Nras. This observation requires further investigation with an adequate statistical methodology to determine its exact place among the other known survival prognostic factors for AML and MDS and more studies should be focus on studying the prognosis between AML and MDS patients and the subtype of ras even special codon mutations.
